+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronavirus Disease 2019 (COVID-19) Company Impact - Moderna Inc

  • PDF Icon

    Company Profile

  • 30 Pages
  • June 2020
  • GlobalData
  • ID: 5117334
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This report gives an important expert analysis on how COVID-19 will affect Moderna Incorporated. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.


  • The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Moderna Inc. performance.
  • Moderna is a pipeline biotech company
  • Moderna’s focus is on mRNA-based prophylactic and therapeutic vaccines
  • Moderna’s pipeline is most active in early stages of drug development
  • mRNA-1273 is Moderna’s main weapon against COVID-19

Reasons to Buy

  • An overview of how Moderna Inc. will be affected by the COVID-19 pandemic.

Table of Contents

1. Executive Summary
2. Company Overview
  • Key Stats
  • Sales Forecast Overview

3. Regional Analysis
  • COVID-19 Spread vs. Location of Moderna Inc. Trials
  • COVID-19 vs. Non-COVID-19 Trials

4. Operational Reaction of COVID-19
  • mRNA-1273 Developed Using Proprietary mRNA Technology
  • Insights Exclusive Intel
  • Global Analyst Consensus Sales Forecast
  • Upcoming Events
  • Disrupted Clinical Trials
  • Recent Deal Activity
  • Recruitment Trends

5. Summary
6. Appendix
  • Methodology
  • About the Publisher
  • Contacts